Advanced Health Intelligence Ltd (AHI)
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Advanced Health Intelligence Ltd (AHI) ist im Technology-Sektor taetig, zuletzt notiert bei $ mit einer Marktkapitalisierung von 0. Bewertet mit 46/100 (vorsichtig) bei Wachstumspotenzial, finanzieller Gesundheit und Momentum.
Zuletzt analysiert: 16. März 2026Advanced Health Intelligence Ltd (AHI) Technologieprofil & Wettbewerbsposition
Advanced Health Intelligence Ltd (AHI) is an Australian technology company specializing in mobile health solutions, offering patented BodyScan, FaceScan, and DermaScan technologies for body dimensioning, vital sign measurement, and dermatological risk assessment. AHI serves the mobile health, telehealth, insurance, and wellness sectors, operating internationally from its base in South Perth.
Investmentthese
Advanced Health Intelligence (AHI) presents a compelling investment case centered on its patented BodyScan, FaceScan, and DermaScan technologies, which cater to the growing demand for mobile health solutions. The company's focus on non-invasive health assessment via smartphone positions it favorably in the expanding telehealth and digital health markets. AHI's ability to serve multiple sectors, including insurance, fitness, and apparel, diversifies its revenue streams and reduces reliance on any single market. Key to AHI's success will be its ability to secure strategic partnerships and integrate its technologies into established platforms. The company's negative profit and gross margins of -154.7% and -138.9% respectively, highlight the need for improved financial performance. AHI's high beta of 1.61 indicates higher volatility compared to the market. Successful commercialization and market penetration are crucial for driving long-term value.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Market capitalization of $0.35 billion reflects investor valuation of AHI's technology and market potential.
- P/E ratio of -5.65 indicates that the company is currently not profitable, requiring careful monitoring of future earnings.
- Negative profit margin of -154.7% highlights the need for improved cost management and revenue generation.
- Negative gross margin of -138.9% suggests challenges in pricing and cost of goods sold, requiring strategic adjustments.
- Beta of 1.61 indicates higher volatility compared to the market, reflecting the speculative nature of the stock.
Wettbewerber & Vergleichsunternehmen
Staerken
- Patented BodyScan technology provides a unique competitive advantage.
- Proprietary FaceScan and DermaScan technologies offer specialized health assessment capabilities.
- Serves multiple sectors, including mobile health, telehealth, insurance, and apparel.
- Established partnerships with key players in the mobile health and telehealth sectors.
Schwaechen
- Negative profit and gross margins indicate financial challenges.
- High beta suggests higher volatility compared to the market.
- Limited brand recognition compared to larger competitors.
- Reliance on technology licensing and partnerships for revenue generation.
Katalysatoren
- Ongoing: Strategic partnerships with telehealth providers to integrate BodyScan and FaceScan technologies.
- Ongoing: Expansion into new geographic markets, particularly in emerging economies.
- Upcoming: Launch of new features and functionalities for BodyScan, FaceScan, and DermaScan technologies by Q4 2026.
- Ongoing: Increasing adoption of mobile health solutions by insurance companies.
- Ongoing: Growing consumer awareness of the benefits of personalized health monitoring.
Risiken
- Potential: Intense competition from larger, more established players in the mobile health market.
- Potential: Regulatory hurdles and data privacy concerns related to health data collection and usage.
- Potential: Technological obsolescence and the need for continuous innovation.
- Ongoing: Negative profit and gross margins indicate financial challenges.
- Potential: Economic downturns and reduced consumer spending on discretionary health and wellness products.
Wachstumschancen
- Expansion into the telehealth market presents a significant growth opportunity for AHI. The telehealth market is projected to reach $550 billion by 2027, driven by increasing demand for remote healthcare services. AHI's BodyScan and FaceScan technologies can be integrated into telehealth platforms to provide remote health assessments, enabling healthcare providers to monitor patients' health remotely and provide timely interventions. This expansion requires strategic partnerships with telehealth providers and healthcare organizations.
- Penetration of the life and health insurance sector offers substantial growth potential. Insurance companies are increasingly using digital health solutions to assess risk, personalize premiums, and improve customer engagement. AHI's technologies can provide insurers with valuable data on policyholders' health status, enabling them to offer tailored insurance products and incentivize healthy behaviors. This opportunity requires collaboration with insurance companies and demonstration of the accuracy and reliability of AHI's technologies.
- Growth in the fitness and wellness market provides another avenue for expansion. Consumers are increasingly using mobile apps and wearable devices to track their fitness and wellness goals. AHI's BodyScan technology can be integrated into fitness apps to provide users with detailed body composition analysis, helping them to track their progress and optimize their training regimens. This requires partnerships with fitness app developers and wearable device manufacturers.
- Entering the consumer apparel sector offers a unique growth opportunity for AHI. The company's BodyScan technology can be used to provide personalized clothing recommendations, ensuring a better fit and reducing returns. This requires collaboration with apparel retailers and online marketplaces to integrate AHI's technology into their platforms. The market for personalized apparel is growing, driven by increasing demand for customized products and improved online shopping experiences.
- International expansion, particularly into emerging markets, presents a significant growth opportunity. Many emerging markets lack access to traditional healthcare infrastructure, making mobile health solutions particularly valuable. AHI's technologies can provide affordable and accessible health assessments to underserved populations, improving health outcomes and reducing healthcare costs. This requires strategic partnerships with local healthcare providers and government agencies.
Chancen
- Expansion into the telehealth market driven by increasing demand for remote healthcare services.
- Penetration of the life and health insurance sector with risk assessment solutions.
- Growth in the fitness and wellness market with body composition analysis tools.
- Entering the consumer apparel sector with personalized clothing recommendations.
Risiken
- Intense competition from larger, more established players in the mobile health market.
- Regulatory hurdles and data privacy concerns related to health data collection and usage.
- Technological obsolescence and the need for continuous innovation.
- Economic downturns and reduced consumer spending on discretionary health and wellness products.
Wettbewerbsvorteile
- Patented BodyScan technology provides a unique competitive advantage.
- Proprietary FaceScan and DermaScan technologies offer specialized health assessment capabilities.
- Established partnerships with key players in the mobile health and telehealth sectors.
- Integration of technologies into existing mobile applications and platforms.
- First-mover advantage in the mobile health assessment market.
Ueber AHI
Advanced Health Intelligence Ltd, formerly known as MyFiziq Limited, was incorporated in 2014 and is based in South Perth, Australia. The company operates as a mobile application and technology development firm, focusing on innovative solutions for health assessment and monitoring. AHI's core product is BodyScan, a patented technology that allows users to measure and assess their body dimensions using a smartphone. This technology provides detailed body composition analysis, which is valuable for various applications, including fitness, wellness, and apparel sizing. In addition to BodyScan, AHI offers FaceScan, a technology that measures vital signs and assesses risks associated with cardiovascular disease, heart attack, and stroke. This non-invasive method uses facial scanning to detect subtle indicators of health risks, providing users with early warnings and insights into their cardiovascular health. The company also provides DermaScan, a dermatological scanner that analyzes skin conditions and identifies potential dermatological issues. AHI serves a diverse range of sectors, including mobile health and telehealth, life and health insurance, fitness and wellness, and consumer apparel. By providing accurate and accessible health data through mobile devices, AHI aims to empower individuals to take control of their health and well-being. The company's technologies are designed to be easily integrated into existing mobile applications and platforms, making them accessible to a wide audience. AHI's evolution from MyFiziq to Advanced Health Intelligence reflects its commitment to expanding its technological capabilities and addressing a broader range of health-related applications.
Was das Unternehmen tut
- Develops and patents BodyScan technology for body dimensioning using smartphones.
- Provides FaceScan technology for measuring vital signs and assessing cardiovascular risks.
- Offers DermaScan, a dermatological scanner for analyzing skin conditions.
- Serves mobile health and telehealth sectors with remote health assessment tools.
- Caters to life and health insurance companies for risk assessment and personalized premiums.
- Supports the fitness and wellness industry with body composition analysis for consumers.
- Partners with consumer apparel companies for personalized clothing recommendations.
Geschaeftsmodell
- Technology licensing to mobile health and telehealth providers.
- Subscription-based access to BodyScan, FaceScan, and DermaScan technologies.
- Partnerships with insurance companies for risk assessment services.
- Integration of BodyScan into fitness apps and wearable devices.
- Collaboration with apparel retailers for personalized clothing recommendations.
Branchenkontext
Advanced Health Intelligence operates within the rapidly evolving mobile health (mHealth) market, which is experiencing significant growth due to increasing smartphone penetration and rising healthcare costs. The industry is characterized by intense competition, with numerous companies offering digital health solutions. AHI differentiates itself through its patented BodyScan, FaceScan, and DermaScan technologies, which provide unique and non-invasive health assessment capabilities. The company's success depends on its ability to effectively compete with larger, more established players and capitalize on the growing demand for accessible and personalized healthcare solutions.
Wichtige Kunden
- Mobile health and telehealth providers seeking remote health assessment tools.
- Life and health insurance companies requiring risk assessment and personalized premiums.
- Fitness and wellness companies offering body composition analysis to consumers.
- Consumer apparel companies aiming to provide personalized clothing recommendations.
- Individual consumers interested in tracking their health and fitness.
Finanzdaten
Chart & Info
Advanced Health Intelligence Ltd (AHI) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
-
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Are Secretly Monitoring But Not Talking About Yet
benzinga · 18. Aug. 2023
-
Why NICE Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
benzinga · 17. Aug. 2023
-
Why Modular Medical Shares Are Trading Higher By 34%; Here Are 20 Stocks Moving Premarket
benzinga · 17. Aug. 2023
-
Stocks That Hit 52-Week Lows On Friday
benzinga · 21. Okt. 2022
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer AHI.
Kursziele
Wall-Street-Kurszielanalyse fuer AHI.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von AHI auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Aktuelle Nachrichten
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Are Secretly Monitoring But Not Talking About Yet
Why NICE Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Why Modular Medical Shares Are Trading Higher By 34%; Here Are 20 Stocks Moving Premarket
Stocks That Hit 52-Week Lows On Friday
Fuehrung: Scott Montgomery
CEO
Scott Montgomery serves as the CEO of Advanced Health Intelligence Ltd, leading a team of 32 employees. His background includes extensive experience in technology and business development, with a focus on driving innovation and growth. Prior to joining AHI, Montgomery held leadership positions in various technology companies, where he was responsible for developing and executing strategic initiatives. His expertise lies in identifying market opportunities, building strategic partnerships, and scaling technology businesses.
Erfolgsbilanz: Under Scott Montgomery's leadership, Advanced Health Intelligence Ltd has focused on expanding its technology portfolio and market reach. Key achievements include securing patents for BodyScan, FaceScan, and DermaScan technologies, as well as establishing partnerships with key players in the mobile health and telehealth sectors. Montgomery has also overseen the company's transition to Advanced Health Intelligence, reflecting its commitment to expanding its technological capabilities and addressing a broader range of health-related applications.
Advanced Health Intelligence Ltd ADR-Informationen Gesponsert
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company trading on U.S. stock exchanges. For AHI, as an ADR, it allows U.S. investors to invest in the Australian-based Advanced Health Intelligence Ltd without the complexities of cross-border transactions. The ADR represents a specific number of AHI's ordinary shares held by a depositary bank.
- Heimatmarkt-Ticker: Australian Securities Exchange (ASX), Australia
- ADR-Stufe: 2
- ADR-Verhaeltnis: 1:1
AHI Technology Aktien-FAQ
What are the key factors to evaluate for AHI?
Advanced Health Intelligence Ltd (AHI) currently holds an AI score of 46/100, indicating low score. Key strength: Patented BodyScan technology provides a unique competitive advantage.. Primary risk to monitor: Potential: Intense competition from larger, more established players in the mobile health market.. This is not financial advice.
How frequently does AHI data refresh on this page?
AHI prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven AHI's recent stock price performance?
Recent price movement in Advanced Health Intelligence Ltd (AHI) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Patented BodyScan technology provides a unique competitive advantage.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider AHI overvalued or undervalued right now?
Determining whether Advanced Health Intelligence Ltd (AHI) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying AHI?
Before investing in Advanced Health Intelligence Ltd (AHI), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding AHI to a portfolio?
Potential reasons to consider Advanced Health Intelligence Ltd (AHI) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Patented BodyScan technology provides a unique competitive advantage.. Additionally: Proprietary FaceScan and DermaScan technologies offer specialized health assessment capabilities.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of AHI?
Yes, most major brokerages offer fractional shares of Advanced Health Intelligence Ltd (AHI) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track AHI's earnings and financial reports?
Advanced Health Intelligence Ltd (AHI) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for AHI earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- Financial data may be subject to change.
- Analyst opinions may vary.
- Investment decisions should be based on individual risk tolerance and due diligence.